[Skip to Navigation]
September 1990

Use of Apraclonidine in the Treatment of Acute Angle Closure Glaucoma

Author Affiliations

New York, NY
Steven M. Podos is a consultant to Alcon Laboratories Inc, Fort Worth, Tex. Neither author has any other commercial or proprietary interest in Alcon or its product, Iopidine.

Arch Ophthalmol. 1990;108(9):1208-1209. doi:10.1001/archopht.1990.01070110024005

To the Editor.  —Previous studies have found that apraclonidine is able to blunt the rise in intraocular pressure that follows anterior segment laser procedures. However, to our knowledge, no one to date has reported the efficacy of another possible short-term use of apraclonidine, namely, the treatment of acute angle-closure glaucoma.

Report of a Case.  —A patient was recently examined with a history of elevated intraocular pressures and minimal visual field loss. Her medications included 0.5% levobunolol twice daily in both eyes and 2% pilocarpine four times daily in both eyes, both of which she had used 2 hours prior to examination. Pupil diameters were 2 mm in both eyes. The patient's intraocular pressures were 21 mm Hg in both eyes. By gonioscopic examination, one third to one half of the trabecular meshwork was visible in both eyes with a steep configuration of the peripheral iris and no peripheral anterior synechias.

Add or change institution